According to the U.S. Food and Drug Administration (FDA), the FDA has launched a searchable tobacco product database. This is a new user-friendly list that allows individuals to search for tobacco products (including e-cigarettes) legally available for sale in the United States. The database is designed to provide key information to the public, particularly retailers, all in one easily accessible place. This database is updated monthly and can be accessed at www.fda.gov/searchtobacco.
In the database, the FDA provides information on three categories of products:
- New tobacco products authorized for the market through one of three marketing pathways by the FDA;
- Existing tobacco products established through voluntary determinations (on the market since February 15, 2007);
- Temporary tobacco products that have been removed from review.
"The Center for Tobacco Products (CTP) remains committed to providing information that enhances transparency in a useful, timely, and user-friendly manner. We hope this database will become an asset to all parties, including retailers, and will be used to promote compliance with regulations," said Dr. Brian King, Director of the FDA Center for Tobacco Products.
At the time of launch, the database contained nearly 17,000 tobacco products, with over 12,000 being existing tobacco products. For each entry, the FDA provides information about the tobacco product, including the product name, company, category, subcategory, authorized agency for sale in the US, and the date of FDA action.
In addition, the database also includes links to regulatory and scientific documents, such as ordering letters, decision summaries, as well as environmental assessments (EAs) and related documents associated with tobacco product applications.
In order to help explain some terminology and background information of the database content, the FDA has also developed a searchable Tobacco Product Database - Additional information webpage. This webpage also includes answers to potential questions about the database, including questions about unauthorized products pending applications. Generally, the FDA cannot provide information about pending applications to protect proprietary information. Additionally, for new products that require authorization, a pending application does not mean that the product can be safely marketed.
The launch of this public database is part of the center's ongoing commitment to providing resources for regulated industries and clearly communicating agency actions to the public. Other recent activities aimed at enhancing transparency include the listing of activities in the center's quarterly updates on evaluations conducted by the Reagan-Yudell Foundation.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
